| Crystal Research and Technology |
The crystal structure of the title complex has been solved using X-ray diffraction data. The compound crystallizes from aqueous ethanol solvent in the triclinic system, space group P-1, with unit cell parameters: a = 8.9532(1), b = 12.7423(3), c = 14.9012(3)Å, α = 73.767(1), β = 75.322(1), γ = 77.496(1)°, Z = 2, V = 1559.4(5) Å3. The trial structure was determined by automated Patterson methods and subsequent difference Fourier techniques using DIRDIF98 and refined to a final R-factor of 0.064. The copper ion Cu1 adopts a (4+1) square-pyramidal geometry defined by the tridentate N-salicylidimine dianions and the neutral monodentate pyridine ligand in the basal plane. The apical position is occupied by a solvent methanol molecule at a distance of 2.341(4) Å. The copper Cu2 adopts a square-planar geometry.
Keywords: metalloenzymes, radiopharmaceuticals, square-pyramidal, salicylidimine, half-boat conformation and intramolecular hydrogen bonds